Livongo Health (LVGO) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-38983
Entity Registrant Name	Livongo Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-3542036
Entity Address, Address Line One	150 West Evelyn Avenue
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94041
City Area Code	866
Local Phone Number	435-5643
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	LVGO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		97,817
Entity Central Index Key	0001639225
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 218,228	$ 241,738
Short-term investments	150,000	150,000
Accounts receivable, net of allowance for doubtful accounts of $1,385 and $1,245 as of March 31, 2020 and December 31, 2019, respectively	52,446	40,875
Inventories	19,245	28,983
Deferred costs, current	22,595	16,051
Prepaid expenses and other current assets	13,869	9,860
Total current assets	476,383	487,507
Property and equipment, net	12,835	10,354
Operating lease right-of-use assets	17,189
Restricted cash, noncurrent	1,270	1,270
Goodwill	35,801	35,801
Intangible assets, net	15,773	16,469
Deferred costs, noncurrent	10,495	5,700
Other noncurrent assets	215	3,460
TOTAL ASSETS	569,961	560,561
Current liabilities:
Accounts payable	8,509	8,362
Accrued expenses and other current liabilities	29,068	27,801
Deferred revenue, current	5,351	3,945
Advance payments from partner, current	1,767	1,767
Total current liabilities	44,695	41,875
Operating lease liabilities, noncurrent	15,476
Deferred revenue, noncurrent	748	654
Advance payment from partner, noncurrent	7,754	7,754
Other noncurrent liabilities	0	2,914
TOTAL LIABILITIES	68,673	53,197
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, par value of $0.001 per share; 100,000 shares authorized as of March 31, 2020 and December 31, 2019, respectively; zero shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	0	0
Common stock, par value of $0.001 per share; 900,000 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 97,293 and 95,301 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	97	95
Additional paid-in capital	670,962	671,467
Accumulated deficit	(169,771)	(164,198)
TOTAL STOCKHOLDERS’ EQUITY	501,288	507,364
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY	$ 569,961	$ 560,561

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 1,385	$ 1,245
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	900,000,000	900,000,000
Common stock, shares issued (in shares)	97,293,000	95,301,000
Common stock, shares outstanding (in shares)	97,293,000	95,301,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue	$ 68,823	$ 32,067
Cost of revenue	18,108	9,863
Gross profit	50,715	22,204
Operating expenses:
Research and development	13,997	8,994
Sales and marketing	27,655	14,643
General and administrative	15,846	14,114
Change in fair value of contingent consideration	84	674
Total operating expenses	57,582	38,425
Loss from operations	(6,867)	(16,221)
Other income, net	1,315	462
Loss before provision for income taxes	(5,552)	(15,759)
Provision for (benefit from) income taxes	21	(1,388)
Net loss	(5,573)	(14,371)
Accretion of redeemable convertible preferred stock	0	(41)
Net loss attributable to common stockholders	$ (5,573)	$ (14,412)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.06)	$ (0.79)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	95,543	18,207

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Restricted Stock Awards	Restricted Stock AwardsCommon Stock	Restricted Stock AwardsAdditional Paid-in Capital	Restricted stock unitsCommon Stock
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Dec. 31, 2018	58,615
Redeemable convertible preferred stock, outstanding at beginning of period at Dec. 31, 2018	$ 236,929
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 41
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Mar. 31, 2019	58,615
Redeemable convertible preferred stock, outstanding at end of period at Mar. 31, 2019	$ 236,970
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2018		17,691
Stockholders' equity (deficit) at beginning of period at Dec. 31, 2018	(91,806)	$ 18	$ 21,789	$ (113,613)
Stockholders' Equity
Accretion of redeemable convertible preferred stock	(41)		(41)
Issuance of common stock upon exercise of stock options (in shares)		454
Issuance of common stock upon exercise of stock options	314		314
Issuance of stock awards (in shares)		491				982
Issuance of stock awards	0	$ 1	(1)		$ 0	$ 1	$ (1)
Stock-based compensation expense	5,526		5,526
Net loss	(14,371)			(14,371)
Common stock, shares outstanding at end of period (in shares) at Mar. 31, 2019		19,618
Stockholders' equity (deficit) at end of period at Mar. 31, 2019	$ (95,693)	$ 20	27,586	(123,299)
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Dec. 31, 2019	0
Redeemable convertible preferred stock, outstanding at beginning of period at Dec. 31, 2019	$ 0
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 0
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Mar. 31, 2020	0
Redeemable convertible preferred stock, outstanding at end of period at Mar. 31, 2020	$ 0
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2019		95,301
Stockholders' equity (deficit) at beginning of period at Dec. 31, 2019	$ 507,364	$ 95	671,467	(164,198)
Stockholders' Equity
Issuance of common stock upon exercise of stock options (in shares)	1,247	1,247
Issuance of common stock upon exercise of stock options	$ 1,722	$ 1	1,721
Issuance of stock awards (in shares)								1,120
Issuance of stock awards	0	$ 1	(1)
Tax withholding on releasing of restricted stock units (in shares)		(375)
Tax withholding on releasing of stock awards	(10,564)		(10,564)
Stock-based compensation expense	8,339		8,339
Net loss	(5,573)			(5,573)
Common stock, shares outstanding at end of period (in shares) at Mar. 31, 2020		97,293
Stockholders' equity (deficit) at end of period at Mar. 31, 2020	$ 501,288	$ 97	$ 670,962	$ (169,771)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,573)	$ (14,371)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,180	696
Amortization of intangible assets	696	564
Non-cash operating lease cost	1,100
Change in fair value of contingent consideration	84	674
Allowance for doubtful accounts	235	98
Stock-based compensation expense	8,063	5,510
Deferred income taxes	0	(1,396)
Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable, net	(11,806)	(11,916)
Inventories	9,738	472
Deferred costs	(11,196)	(5,510)
Prepaid expenses and other assets	(764)	(2,609)
Accounts payable	(98)	3,142
Accrued expenses and other liabilities	(3,024)	(480)
Operating lease liabilities	(546)
Deferred revenue	1,500	75
Advance payments from partner	0	(136)
Net cash used in operating activities	(10,411)	(25,187)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(1,762)	(340)
Capitalized internal-use software costs	(1,325)	(1,284)
Acquisitions, net of cash acquired	0	(27,435)
Net cash used in investing activities	(3,087)	(29,059)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options, net of repurchases	1,722	314
Payment of deferred offering costs	(286)	0
Payment of deferred acquisition-related contingent consideration	(884)	0
Taxes paid related to net share settlement of equity awards	(10,564)	0
Net cash (used in) provided by financing activities	(10,012)	314
Net decrease in cash, cash equivalents, and restricted cash	(23,510)	(53,932)
Cash, cash equivalents, and restricted cash, beginning of period	243,008	109,107
Cash, cash equivalents, and restricted cash, end of period	219,498	55,175
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	218,228	54,996
Restricted cash	1,270	179
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock	0	41
Purchases of property and equipment included in accounts payable and accrued liabilities	491	112
Contingent consideration liability	0	3,300
Unpaid working capital adjustment related to myStrength acquisition	0	119
Capitalized internal-use software costs in accounts payable and accrued liabilities	(141)	(163)
Common Stock
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Unpaid offering costs	$ 0	$ 331

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Nature of the Business Livongo Health, Inc. (“we”, “us”, “the Company”, or “Livongo”) was incorporated in the state of Delaware on October 16, 2008, under the name of EosHealth, Inc. In September 2014, we changed our name to Livongo Health, Inc. Livongo empowers people with chronic conditions to live better and healthier lives. We have created a unified platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions to help our members lead better lives. We currently offer Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. We create consumer-first experiences with high member satisfaction, measurable, sustainable health outcomes, and more cost-effective care for our members and our clients. This approach is leading to better clinical and financial outcomes while also creating a better experience for people with chronic conditions and their care team of family, friends, and medical professionals. Our headquarters are located in Mountain View, California, and we serve customers throughout North America. Initial Public Offering In July 2019, we completed our initial public offering ("IPO") in which we issued and sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We received net proceeds of $377.5 million , after deducting underwriting discounts and commissions of $28.6 million and offering costs of $2.4 million . Offering costs were capitalized and consisted of fees and expenses incurred in connection with the sale of our common stock in the IPO, including the legal, accounting, printing and other IPO-related costs. Upon completion of the IPO, these deferred offering costs were reclassified to stockholders’ equity and recorded against the proceeds from the offering. Immediately prior to the closing of the IPO, all 58,615,488 shares of our then-outstanding redeemable convertible preferred stock automatically converted into 58,615,488 shares of common stock at their respective conversion ratios and we reclassified $236.9 million of redeemable convertible preferred stock to additional paid-in capital and $0.1 million to common stock on our condensed consolidated balance sheet. Reverse Stock Split In June 2019, our board of directors and stockholders approved a 1-for-2 reverse stock split of our common stock and redeemable convertible preferred stock, which was effected on June 27, 2019 pursuant to an amendment to our amended and restated certificate of incorporation. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All references to redeemable convertible preferred stock, common stock, options to purchase common stock, restricted stock awards, restricted stock units, common stock warrants, per share data, and related information included in the accompanying condensed consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented. Liquidity and Capital Resources We have incurred losses since inception. As of March 31, 2020 , we had an accumulated deficit of $169.8 million. During the three months ended March 31, 2020 , we incurred a net loss of $5.6 million and used $10.4 million of cash in operating activities. During the three months ended March 31, 2019 , we incurred a net loss of $14.4 million and used $25.2 million in operating activities. As described above, we received net proceeds of $377.5 million from our IPO in July 2019. Prior to our IPO, we primarily funded our operations through the sale of our redeemable convertible preferred stock. The continued execution of our long-term business plan may require us to explore financing options such as issuance of equity or debt instruments. While we have historically been successful in obtaining equity financing, there can be no assurance that such additional financing, if necessary, will be available or, if available, that such financings can be obtained on satisfactory terms. Risks and Uncertainties

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Livongo Health, Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP. The accompanying interim condensed consolidated balance sheets as of March 31, 2020 , the interim condensed consolidated statements of operations and the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three months ended March 31, 2020 and 2019 , and the interim condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. These interim condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, include all adjustments necessary to fairly state our financial position as of March 31, 2020 , the results of our operations for the three months ended March 31, 2020 and 2019 and result of our cash flows for the three months ended March 31, 2020 and 2019 . The financial data and other financial information disclosure in the notes to these interim condensed consolidated financial statements related to the three months periods are also unaudited. The results for the three months ended March 31, 2020 are not necessarily indicative of the operating results expected for the year ending December 31, 2020 or any future period. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 24, 2020. We have revised our condensed consolidated statements of operations and cash flows for the three months ended March 31, 2019 to reflect the adoption of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASC 606, as of January 1, 2019, on a modified retrospective basis. This revision was made because our financial statements presented in our Quarterly Report on Form 10-Q for the period ended March 31, 2019 were prepared in accordance with ASC 605, the prior accounting standard. In addition, we made other adjustments to our financial results for the first quarter through the third quarter of 2019 to correct errors that consist of (i) a $1.9 million total adjustment for the capitalization and amortization of device costs for Livongo for Hypertension and Livongo for Prediabetes and Weight Management, (ii) a $1.2 million total reduction of sales and marketing expenses for the capitalization and amortization of certain sales commissions, and (iii) a $0.4 million increase in sales and marketing expenses. We evaluated the materiality of these revisions, quantitatively and qualitatively, and determined that these revisions were not material to any of our previously issued condensed consolidated financial statements. Comprehensive Loss For the three months ended March 31, 2020 and 2019 , there was no difference between comprehensive loss and net loss. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. Such estimates, judgments, and assumptions include: revenue recognition, allowance for doubtful accounts, the period of benefit for deferred commissions, the period of benefit for deferred device costs, estimated costs for capitalized internal-use software, assessment of the useful life and recoverability of long-lived assets, fair values of stock-based awards, contingent consideration in business combinations, the incremental borrowing rate ("IBR") applied in lease accounting, and income taxes. Actual results could be different from these estimates. While the COVID-19 pandemic has not had a material adverse impact on our results of operations to date, our estimates for revenue recognition and allowance for doubtful accounts, as well as our other estimates, judgments, and assumptions, may be materially and adversely different from our actual results as a result of the COVID-19 pandemic. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected. Emerging Growth Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards. Concentration of Risk Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, certificates of deposit, and accounts receivable. We maintain our cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. We invest our cash equivalents in highly rated money market funds and short-term investments in certificates of deposit. We have not experienced any losses in such accounts. We believe we are not exposed to any significant credit risk on cash, cash equivalents, investments and restricted cash and perform periodic evaluations of the credit standing of such institutions. Our sales are predominately to self-insured employers, healthcare providers, and insurance carriers located throughout North America. Accounts receivable are recorded at the invoiced amount, and are stated at realizable value, net of an allowance for doubtful accounts. We perform ongoing assessments of our clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. We have not experienced material credit losses from our accounts receivable. Significant clients and partners are those which represent 10% or more of our net accounts receivable balance or revenue during the period at each respective consolidated balance sheet date. There were no clients that represented 10% or more of our revenue or accounts receivable balance for the periods presented. For each significant partner that represented 10% or more of our accounts receivable balance or revenue during the periods presented, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended March 31, March 31, December 31, 2020 2019 2020 2019 Partner A 24 % 25 % 20 % 23 % Partner B 18 % 23 % 22 % 25 % We utilize a limited number of manufacturing vendors to build and assemble our products. The hardware components included in our devices are sourced from various suppliers by the manufacturer and are principally industry standard parts and components that are available from multiple vendors. Quality or performance failures of the glucometer or changes in the contractors’ or vendors’ financial or business condition could disrupt our ability to supply quality products to our clients and thereby have a material adverse impact on our business, financial condition and results of operations. Recent Accounting Pronouncements Adopted in Fiscal 2020 Leases: In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance (collectively, "ASC 842"), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU is effective for us for the interim periods and year ending December 31, 2020. Early adoption is permitted. We adopted ASC 842 on January 1, 2020 using the modified retrospective approach by electing to use the optional transition method which allows us to continue to apply the previous guidance, including disclosure requirements, in the comparative periods presented. We elected to use certain practical expedients permitted under the transition guidance within the new guidance, which allows us to carry forward the historical accounting relating to lease identification and classification for existing leases upon adoption. We also elected not to use the hindsight practical expedient in determining the lease term and impairment of the operating lease right-of-use ("ROU") assets and elected not to record operating leases with an initial term of 12 months or less on our condensed consolidated balance sheets. We elected not to separate lease and non-lease components for all classes of underlying assets. Adoption of the new lease standard resulted in the recording of ROU assets and operating lease liabilities of approximately $18.1 million and $18.6 million , respectively, as of January 1, 2020. The difference between the ROU assets and operating lease liabilities primarily relates to deferred rent of $0.5 million recorded in accordance with the previous lease guidance. The adoption had no impact on total cash flows from operations other than a change within operating cash flows. We determine if an arrangement is or contains a lease at inception. Our lease agreements do not contain any material options to extend or terminate leases, any material residual value guarantees, any material restrictions or covenants, or any material variable lease payments. Any variable lease payments consist of common area maintenance, taxes and other costs and are expensed as incurred. We have performed an evaluation of our other contracts with customers and suppliers in accordance with ASC 842 and have determined that, none of our other contracts contain a lease. ROU assets represent our right to use an underlying asset for the lease term, while operating lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. In determining the present value of lease payments, we use our IBR based on the information available at the lease commencement date, including the lease term, for operating leases. The incremental borrowing rate is a hypothetical rate based on our understanding of what our credit rating would be for a secured borrowing in the country where the lease was executed. Upon adoption, the ROU asset was valued at the amount of the operating lease liabilities adjusted for lease incentives, prepaid rent, and deferred rent as of January 1, 2020. The adoption of the new standard resulted in changes to our accounting policies for leases and in additional disclosures. See Note 8. Stock-Based Compensation: In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . The standard simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. ASU No. 2018-07 is effective for us for the interim periods and the year beginning January 1, 2020. Early adoption is permitted. We adopted this new standard using a prospective method on January 1, 2020. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. Disclosure of Fair Value Measurement: In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including interim reporting periods within those fiscal years. ASU 2018-13 is effective for us for the interim periods and the year beginning January 1, 2020. We adopted the new standard using a prospective method effective on January 1, 2020. The adoption of this ASU resulted in additional disclosures in Note 6 of our condensed consolidated financial statements. New Accounting Pronouncements Not Yet Adopted Credit Losses: In June 2018, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard requires a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected, with further clarifications made more recently. For trade receivables, loans, and other financial assets, we will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available-for-sale debt securities are required to be recorded through an allowance for credit losses rather than a reduction in the amortized cost basis of the securities. This new standard is effective for us for the interim periods within and the year ending December 31, 2020. Early adoption is permitted. We are currently evaluating the impact of this ASU on our consolidated financial statements. Cloud Computing Arrangements Implementation Costs : In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. This ASU is effective for us for the year ending December 31, 2021, and interim periods within the year ending December 31, 2022. Early adoption is permitted. This standard could be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact of this ASU on our consolidated financial statements and expect to apply this standard using the prospective transition method. Income Taxes : In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies that accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amending existing guidance to improve consistent application. This new standard is effective for our interim periods and year beginning January 1, 2022. Early adoption is permitted. Most amendments within this standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

Revenue, Deferred Revenue, and

Revenue, Deferred Revenue, and Deferred Costs and Other	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue, Deferred Revenue and Deferred Costs and Other	Revenue, Deferred Revenue and Deferred Costs and Other Deferred Revenue Deferred revenue activity is as follows (in thousands): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 4,599 $ 2,051 Amounts billed but unrecognized 3,140 1,378 Revenue recognized (1,640 ) (1,309 ) Assumed from business combination — 1,407 Balance at end of period $ 6,099 $ 3,527 Balance at the end of period (in thousands): March 31, December 31, 2020 2019 Deferred revenue, current $ 5,351 $ 3,945 Deferred revenue, noncurrent 748 654 Total deferred revenue $ 6,099 $ 4,599 We expect to recognize $5.4 million of revenue in the next 12 months and $0.7 million of revenue thereafter, related to future performance obligations that were unsatisfied or partially satisfied as of March 31, 2020 . Accrued Rebates Accrued rebates represent the amounts in client contracts that are subject to pricing adjustments based on various performance metrics, such as member satisfaction scores, cost savings guarantees and health outcome guarantees, which if not met typically require us to refund a portion of the per participant per month fee paid. We defer an estimate of the amount of consideration that we expect to refund to our clients from the monthly per participant per month fee until the performance metric is met. As of March 31, 2020 and December 31, 2019 , accrued rebates of $1.7 million and $1.2 million, respectively, were recorded within accrued expenses and other current liabilities on our condensed consolidated balance sheets. The activity is as follows (in thousands): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 1,152 $ 609 ASC 606 adoption date impact adjustment — (222 ) Amount deferred 776 193 Revenue recognized (198 ) (2 ) Payments — (45 ) Balance at end of period $ 1,730 $ 533 Deferred Costs and Other Deferred costs and other activity is as follows (in thousands): Three Months Ended March 31, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 18,579 $ 2,988 $ 184 $ 21,751 Additions 17,144 174 418 17,736 Revenue recognized — — (130 ) (130 ) Cost of revenue recognized (5,973 ) — — (5,973 ) Sales and marketing expenses recognized — (294 ) — (294 ) Balance at end of period $ 29,750 $ 2,868 $ 472 $ 33,090 Three Months Ended March 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 8,469 $ — $ — $ 8,469 ASC 606 adoption date impact adjustment — 3,692 771 4,463 Additions 8,495 — 112 8,607 Revenue recognized — — (245 ) (245 ) Cost of revenue recognized (2,598 ) — — (2,598 ) Sales and marketing expenses recognized — (254 ) — (254 ) Balance at end of period $ 14,366 $ 3,438 $ 638 $ 18,442 Balance at the end of period (in thousands): March 31, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 20,961 $ 1,162 $ 472 $ 22,595 Deferred costs, noncurrent 8,789 1,706 — 10,495 Total deferred costs $ 29,750 $ 2,868 $ 472 $ 33,090 December 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 14,746 $ 1,121 $ 184 $ 16,051 Deferred costs, noncurrent 3,833 1,867 — 5,700 Total deferred costs $ 18,579 $ 2,988 $ 184 $ 21,751

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combinations	Business Combinations Retrofit Inc. We acquired all of the issued and outstanding shares of Retrofit Inc. (“Retrofit”), a privately-held, Illinois-based entity, and a leading provider of weight-management and disease-prevention programs, through a share purchase agreement (the “Retrofit Purchase Agreement”) in exchange for cash consideration (the “Retrofit Acquisition”) in April 2018. The Retrofit Acquisition provides us with an evidence-based diabetes prevention program that enhances our data science capabilities and our expertise in holistic weight management including nutrition, exercise and mindset. The total consideration transferred as part of the Retrofit Acquisition consisted of a cash payment on the closing date, adjusted for customary closing adjustments, of $12.4 million . Upon the close of the Retrofit Acquisition, as part of the Retrofit Purchase Agreement, we placed in escrow an earn-out consideration of $7.0 million held by a third-party escrow agent to be released to the former stockholders of Retrofit contingent upon achieving future qualified member targets as determined on December 31, 2019 , 2020 , and 2021 (the “Retrofit Contingent Consideration”). We recorded a corresponding escrow asset of $7.0 million on our condensed consolidated balance sheet upon the close of the acquisition. We estimated the fair value of the Retrofit Contingent Consideration to be $6.2 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration resulted in total purchase consideration of $18.6 million . The Retrofit Contingent Consideration is subject to remeasurement at each reporting date until the payments are released from escrow, with the remeasurement adjustment reported in our condensed consolidated statements of operations. For the three months ended March 31, 2020 and 2019 , the fair value of the Retrofit Contingent Consideration had increased and we recorded an expense of $0.1 million and less than $0.1 million , respectively, within the change in fair value of contingent consideration on our condensed consolidated statement of operations. In April 2019, we released $1.8 million from the escrow deposit, of which $1.3 million was paid to the former stockholders of Retrofit. As of March 31, 2020 and December 31, 2019 , the remaining Retrofit Contingent Consideration was $2.9 million and $2.8 million, respectively. myStrength, Inc. In February 2019, we acquired all of the issued and outstanding shares of myStrength, Inc. (“myStrength”), a privately-held entity based in Denver, Colorado, and a leading provider of digital behavioral health solutions through an agreement and plan of merger (the “myStrength Purchase Agreement”) in exchange for cash consideration (the “myStrength Acquisition”). The myStrength Acquisition has enabled us to more fully address the health of the whole person by bringing behavioral health conditions including depression, anxiety, stress, substance use disorder, chronic pain, opioid addiction and recovery, and insomnia to our Applied Health Signals solution. The total consideration for the myStrength Acquisition was $30.1 million in cash, subject to a closing adjustment of $0.1 million . As part of the myStrength Purchase Agreement, we are obligated to pay an earn-out consideration up to $5.0 million contingent upon satisfying future milestones for the year ended December 31, 2019 (the “myStrength Contingent Consideration”). We estimated the fair value of the myStrength Contingent Consideration to be $3.3 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration, resulted in total purchase consideration of $33.5 million . The myStrength Contingent Consideration was subject to remeasurement at each reporting date until the payments are made, with the remeasurement adjustment reported in our condensed consolidated statements of operations. For the three months ended March 31, 2019 , we increased the fair value of the myStrength Contingent Consideration and recorded an expense of $0.6 million in our condensed consolidated statements of operations. In December 2019, we paid $2.4 million of the myStrength contingent consideration to the former shareholders of myStrength. In the three months ended March 31, 2020, we paid the remaining fair value of the myStrength contingent consideration of $2.6 million . The purchase consideration of $33.5 million was allocated as follows: Amount (in thousands) Cash and cash equivalents $ 2,643 Accounts receivable 1,337 Other current assets 140 Property and equipment 114 Intangible assets 13,900 Other assets 34 Total assets acquired 18,168 Accounts payable 173 Accrued expenses and other liabilities 1,787 Deferred revenue 1,407 Deferred tax liability, net 1,396 Total liabilities assumed 4,763 Goodwill 20,092 Total purchase consideration $ 33,497 The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of the acquisition date: Cost Useful Life (in thousands) (years) Customer relationships $ 4,300 7.0 Developed technology 9,200 7.0 Trade name 400 5.0 Total $ 13,900 The estimated fair values of the intangible assets acquired were determined based on the income approach to measure the fair value of the trade name, customer relationships, and developed technology. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. Additionally, in the first quarter of 2019, we incurred a total of $0.2 million of acquisition-related costs as a result of the myStrength acquisition. Goodwill represents the excess of the purchase consideration over the estimated acquisition date fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill is primarily attributable to expected post-acquisition synergies from integrating myStrength’s assembled workforce and developed technology into our product offerings and cross-selling opportunities. Goodwill recorded is not deductible for income tax purposes. The results of operations of myStrength have been included in our consolidated financial statements from the respective date of purchase. Unaudited Pro Forma Financial Information The following unaudited pro forma information presents the combined results of operations as if the myStrength Acquisition had been completed on January 1, 2018, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of myStrength that was not acquired; (ii) amortization of the acquired intangible assets; (iii) fair value adjustment for deferred revenue; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments. March 31, 2019 (in thousands) Revenue $ 32,666 Net loss $ (13,031 )

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Inventories Inventories of $19.2 million and $29.0 million , as of March 31, 2020 and December 31, 2019 , respectively, consisted of finished goods. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: March 31, December 31, 2020 2019 (in thousands) Prepaid expenses $ 7,170 $ 6,691 Escrow deposit, current 5,342 2,100 Interest receivable 606 504 Prepaid rent 263 352 Short-term deposits 484 201 Other current assets 4 12 Total $ 13,869 $ 9,860 Property and Equipment, Net Property and equipment consisted of the following: March 31, December 31, 2020 2019 (in thousands) Computer, equipment and software $ 3,442 $ 2,218 Furniture and fixtures 1,463 915 Capitalized internal-use software 12,545 11,229 Leasehold improvements 1,664 1,092 Property and equipment 19,114 15,454 Less: accumulated depreciation (6,279 ) (5,100 ) Property and equipment, net $ 12,835 $ 10,354 Depreciation and amortization expense was $1.2 million and $0.7 million for the three months ended March 31, 2020 and 2019 , respectively. Intangible Assets, Net Intangible assets consisted of the following as of March 31, 2020 : Gross Value Accumulated Amortization Net Book Value Weighted- Average Remaining Useful Life (in thousands) (years) Customer relationships $ 8,190 $ (1,479 ) $ 6,711 6.8 Developed technology 11,020 (2,268 ) 8,752 5.4 Trade name 448 (138 ) 310 3.8 Total $ 19,658 $ (3,885 ) $ 15,773 Intangible assets consisted of the following as of December 31, 2019 : Gross Value Accumulated Amortization Net Book Value Weighted- Average Remaining Useful Life (in thousands) (years) Customer relationships $ 8,190 $ (1,227 ) $ 6,963 7.1 Developed technology 11,020 (1,848 ) 9,172 5.7 Trade names 448 (114 ) 334 4.0 Total $ 19,658 $ (3,189 ) $ 16,469 Amortization expense for intangible assets for the three months ended March 31, 2020 and 2019 is as follows: Three Months Ended March 31, 2020 2019 (in thousands) Customer relationships $ 252 $ 209 Developed technology 420 327 Trade names 24 28 Total $ 696 $ 564 The expected future amortization expense related to intangible assets as of March 31, 2020 was as follows: Amount (in thousands) Remainder of 2020 $ 2,073 2021 2,762 2022 2,750 2023 2,494 2024 2,324 Thereafter 3,370 Total $ 15,773 Goodwill Goodwill was $35.8 million as of March 31, 2020 and December 31, 2019 . Through March 31, 2020 , there have no t been any impairment of goodwill. Other Noncurrent Assets Other noncurrent assets consisted of the following: March 31, December 31, 2020 2019 (in thousands) Escrow deposit, noncurrent $ — $ 3,150 Other 215 310 Total $ 215 $ 3,460 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, 2020 2019 (in thousands) Accrued bonus $ 3,304 $ 8,652 Vendor accruals 4,305 3,984 Contingent consideration, current 2,915 3,004 Accrued commissions 3,046 2,611 Accrued payroll and employee benefits 2,545 2,291 Accrued sales and use taxes 194 932 Accrued rebates 1,730 1,152 Employee contribution to ESPP 2,303 1,805 Operating lease liabilities, current 2,877 — Other accrued expenses 5,849 3,370 Total $ 29,068 $ 27,801

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table sets forth the fair value of our financial assets and liabilities by level within the fair value hierarchy: March 31, 2020 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 105,566 $ — $ — $ 105,566 Short-term investment: Certificate of deposit 150,000 — 150,000 Total assets at fair value $ 255,566 $ — $ — $ 255,566 Liabilities Other current liabilities—contingent consideration $ — $ — $ 2,915 $ 2,915 Total liabilities at fair value $ — $ — $ 2,915 $ 2,915 December 31, 2019 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 130,640 $ — $ — $ 130,640 Short-term investment: Certificate of deposit $ 150,000 $ — $ — $ 150,000 Total assets at fair value $ 280,640 $ — $ — $ 280,640 Liabilities Other current liabilities—contingent consideration $ — $ — $ 3,004 $ 3,004 Other noncurrent liabilities—contingent consideration — — 2,411 2,411 Total liabilities at fair value $ — $ — $ 5,415 $ 5,415 Cash, Cash Equivalents and Short-Term Investments Our valuation techniques used to measure the fair value of money market funds are derived from quoted prices in active markets for identical assets or liabilities. Short-term investments, which consist of certificates of deposit with a maturity of 12 months or less, are classified as Level 2 financial assets because they are valued using quoted market price and other observable inputs in active markets for identical securities. Cash, cash equivalents and short-term investments were as follows (in thousands): March 31, 2020 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 112,662 $ — $ — $ 112,662 Money market funds 105,566 — $ — 105,566 Total cash, and cash equivalents 218,228 — — 218,228 Certificate of deposit 150,000 — — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 368,228 $ — $ — $ 368,228 December 31, 2019 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 111,098 $ — $ — $ 111,098 Money market funds 130,640 — — 130,640 Total cash, and cash equivalents 241,738 — — 241,738 Certificate of deposit 150,000 — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 391,738 $ — $ — $ 391,738 Contingent Consideration Liability In connection with the Retrofit Acquisition in April 2018, we recorded a contingent consideration liability, which is payable subject to the achievement of certain targets for 2018, 2019 , and 2020 . In connection with the myStrength Acquisition in February 2019, we recorded a contingent liability, which was payable subject to the achievement of certain targets for 2019 and was paid in February 2020. The fair values of these contingent consideration liabilities were estimated with a Monte Carlo simulation model using Level 3 inputs to assess the probability of us achieving the targets, and any subsequent changes in fair value are recorded in the condensed consolidated statements of operations until settlement. As of March 31, 2020 , the significant inputs for the fair value of the remaining contingent liability included projected qualifying members for fiscal year 2020, weighted-average revenue volatility of 3.82% , weighted-average revenue discount rate of 0.6% , and weighted-average discount rate of 0.17% . See Note 4 for further discussion. As of March 31, 2020 and December 31, 2019 , total contingent consideration liabilities were $2.9 million and $5.4 million, respectively. The following table sets forth the changes in our Level 3 financial liabilities for the periods presented: Three Months Ended March 31, 2020 2019 (in thousands) Beginning balance $ 5,415 $ 5,004 Contingent consideration recorded upon acquisition (Note 4) — 3,300 Change in fair value of contingent consideration (Note 4) 84 674 Payment related to myStrength contingent consideration (Note 4) (2,584 ) — Ending balance $ 2,915 $ 8,978

Revolving Loan

Revolving Loan	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Revolving Loan	Revolving Loan In July 2019, we entered into a Loan and Security Agreement with Silicon Valley Bank ("SVB"). The agreement provides a secured revolving loan facility in an aggregate principal amount of up to $30.0 million with a maturity of any revolving loan thereunder in July 2022. Revolving loans under this facility bear interest at a floating rate equal to the greater of (i) 5.25% or (ii) the prime rate published in the Wall Street Journal, minus 0.25% . Interest on any revolving loan is due and payable monthly in arrears. Our obligations under the Loan and Security Agreement are secured by a security interest on substantially all of our assets, excluding our intellectual property. The Loan and Security Agreement contains a financial covenant along with covenants limiting our ability to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock, and make investments, in each case subject to certain exceptions. The Loan and Security Agreement also contains customary events of default, upon which SVB may declare all or a portion of our outstanding obligations payable to be immediately due and payable. There were no amounts outstanding under the agreement as of March 31, 2020 or December 31, 2019 . Fees incurred under the revolving loan facility during the three months ended March 31, 2020 were not material.

Operating Lease Liabilities

Operating Lease Liabilities	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Operating Lease Liabilities	Operating Lease Liabilities We lease office facilities under operating lease arrangements that have remaining lease terms ranging from 3 to 7 years. Our leases do not contain any material residual value guarantees or restrictive covenants. During the three months ended March 31, 2020, operating lease costs for non-cancelable operating lease costs were $1.1 million . Variable lease costs were $0.2 million for the three months ended March 31, 2020. Sublease income for the three months ended March 31, 2020 were not material. Under ASC 840, the previous lease standard, total rent expense under operating leases during the three months ended March 31, 2019 was $0.6 million . A summary of supplemental lease information is as follows: Three Months Ended March 31, 2020 (in thousands) Weighted average remaining lease term (years) 4.6 Weighted average discount rate 3.8 % Maturities of operating lease liabilities as of March 31, 2020 are as follows: March 31, 2020 (in thousands) Years ending December 31, 2020 (remaining 9 months) $ 3,391 2021 5,094 2022 5,242 2023 5,213 2024 1,799 2025 and thereafter 3,071 Total lease payments 23,810 Less: imputed interest (2,149 ) Less: tenant allowance (3,308 ) Total operating lease liabilities $ 18,353 Reported as: Operating lease liabilities, current (1) $ 2,877 Operating lease liabilities, noncurrent 15,476 Total operating lease liabilities $ 18,353 (1) Included as part of "Accrued expenses and other current liabilities" on the condensed consolidated balance sheets. Future minimum lease payments, net of future sublease income of $0.2 million , under operating leases as of December 31, 2019 under ASC 840, the prior lease standard, were as follows: Net Minimum Lease Payments (in thousands) 2020 $ 3,908 2021 5,055 2022 5,233 2023 5,141 2024 1,756 Thereafter 3,068 Total future minimum payments $ 24,161

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, we become involved in claims and other legal matters arising in the ordinary course of business. We investigate these claims as they arise. Although claims are inherently unpredictable, we are currently not aware of any matters that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial position or cash flows. We record liabilities for legal and other contingencies when losses are probable and estimable. Although the results of litigation and claims are inherently unpredictable, we have not recorded an accrual for such contingencies as we believe that there was not at least a reasonable possibility that we had incurred a material loss with respect to such loss contingencies as of March 31, 2020 , and December 31, 2019 . Indemnification We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, including, but not limited to, clients, business partners, landlords, contractors and parties performing our research and development. Pursuant to these arrangements, we agree to indemnify, hold harmless, and reimburse the indemnified party for certain losses suffered or incurred by the indemnified party as a result of our activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is not material. We maintain commercial general liability insurance and product liability insurance to offset certain of our potential liabilities under these indemnification provisions. In addition, we indemnify our officers, directors and certain key employees while they are serving in good faith in their respective capacities. To date, there have been no claims under these indemnification provisions.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity Redeemable Convertible Preferred Stock In conjunction with our IPO in July 2019, all shares of redeemable convertible preferred stock then outstanding, totaling 58,615,488 shares, were automatically converted into an equivalent number of shares of common stock on a one -to-one basis and their carrying value, totaling $237.0 million , inclusive of accretion of redeemable convertible preferred stock, was reclassified into stockholders’ equity on our condensed consolidated balance sheets. No shares of redeemable convertible preferred stock were issued or outstanding as of March 31, 2020 or December 31, 2019 . Accretion to the redemption price of our redeemable convertible preferred stock was zero and less than $0.1 million for the three months ended March 31, 2020 and 2019 , respectively. Accretion is recognized as a reduction of additional paid-in capital with a corresponding increase to the carrying value of our redeemable convertible preferred stock. Upon completion of the IPO, the accretion rights of our redeemable convertible preferred stock were terminated. Undesignated Preferred Stock In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.001 per share, with rights and preferences, including voting rights, designated from time to time by our board of directors. Common Stock In December 2019, we completed a secondary offering in which certain stockholders sold 2,777,327 shares of common stock at an offering price of $27.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. We did not sell any shares or receive any proceeds in this secondary offering. In July 2019, upon completion of our IPO, we sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We raised net proceeds of $377.5 million , after deducting underwriting discounts and commissions of $28.6 million and offering costs of approximately $2.4 million . In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 900,000,000 shares of common stock with a par value of $0.001 per share. As of March 31, 2020 and December 31, 2019 , we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: March 31, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 12,629 14,020 Outstanding restricted stock units 4,713 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,843 890 Available for future issuance under 2019 Plan 11,866 8,160 Total 32,360 29,709 Common stock warrants outstanding as of March 31, 2020 and December 31, 2019 are as follows: Holder Issue Date Outstanding Shares Exercise Price Exercisable Shares Expiration Date (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695 No common stock warrants were exercised during the three months ended March 31, 2020 .

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Common Stock Warrants	Stockholders’ Equity Redeemable Convertible Preferred Stock In conjunction with our IPO in July 2019, all shares of redeemable convertible preferred stock then outstanding, totaling 58,615,488 shares, were automatically converted into an equivalent number of shares of common stock on a one -to-one basis and their carrying value, totaling $237.0 million , inclusive of accretion of redeemable convertible preferred stock, was reclassified into stockholders’ equity on our condensed consolidated balance sheets. No shares of redeemable convertible preferred stock were issued or outstanding as of March 31, 2020 or December 31, 2019 . Accretion to the redemption price of our redeemable convertible preferred stock was zero and less than $0.1 million for the three months ended March 31, 2020 and 2019 , respectively. Accretion is recognized as a reduction of additional paid-in capital with a corresponding increase to the carrying value of our redeemable convertible preferred stock. Upon completion of the IPO, the accretion rights of our redeemable convertible preferred stock were terminated. Undesignated Preferred Stock In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.001 per share, with rights and preferences, including voting rights, designated from time to time by our board of directors. Common Stock In December 2019, we completed a secondary offering in which certain stockholders sold 2,777,327 shares of common stock at an offering price of $27.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. We did not sell any shares or receive any proceeds in this secondary offering. In July 2019, upon completion of our IPO, we sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We raised net proceeds of $377.5 million , after deducting underwriting discounts and commissions of $28.6 million and offering costs of approximately $2.4 million . In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 900,000,000 shares of common stock with a par value of $0.001 per share. As of March 31, 2020 and December 31, 2019 , we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: March 31, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 12,629 14,020 Outstanding restricted stock units 4,713 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,843 890 Available for future issuance under 2019 Plan 11,866 8,160 Total 32,360 29,709 Common stock warrants outstanding as of March 31, 2020 and December 31, 2019 are as follows: Holder Issue Date Outstanding Shares Exercise Price Exercisable Shares Expiration Date (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695 No common stock warrants were exercised during the three months ended March 31, 2020 .

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation We have the following stock-based compensation plans: the EosHealth, Inc. 2008 Stock Incentive Plan (the “2008 Plan”), the Livongo Health, Inc. 2014 Stock Incentive Plan (the “2014 Plan”), and the 2019 Equity Incentive Plan (the "2019 Plan", and, together with the 2014 Plan and the 2008 Plan, the "Plans"). Our 2019 Plan became effective as of the business day immediately prior to the effective date of our IPO. A total of 8,004,000 shares of our common stock was initially reserved for issuance pursuant to our 2019 Plan. In addition, the shares reserved for issuance under our 2019 Plan include (i) shares that were reserved but unissued under our 2014 Plan as of immediately prior to its termination, plus (ii) shares subject to awards under our 2014 Plan, and our 2008 Plan that, on or after the termination of the 2014 Plan, expire or terminate and shares previously issued pursuant to our 2014 Plan or 2008 Plan, as applicable, that, on or after the termination of the 2014 Plan, are forfeited or repurchased by us (provided that the maximum number of shares that may be added to our 2019 Plan from the 2014 Plan and 2008 Plan is 21,770,029 shares). The number of shares of our common stock available for issuance under our 2019 Plan will also include an annual increase on the first day of each fiscal year beginning on January 1, 2020, equal to the least of: (i) 7,120,000 shares; (ii) 4% of the outstanding shares of our common stock as of the last day of our immediately preceding fiscal year; or (iii) such other amount as our board of directors may determine as of no later than the last day of our immediately preceding fiscal year. Stock Options Stock option activity under the Plans is as follows: Options Outstanding Shares Available for Grant Shares Subject to Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands, except per share data and years) Balance as of December 31, 2019 8,160 14,020 $ 1.85 6.7 $ 325,474 Shares authorized 3,812 — Exercised — (1,247 ) $ 1.38 Forfeited/cancelled 144 (144 ) $ 1.88 Restricted stock units and PSUs granted (726 ) — Restricted stock units and PSUs forfeited 101 — Restricted stock units and PSUs withheld for income taxes 375 — Balance as of March 31, 2020 11,866 12,629 $ 1.89 6.4 $ 336,424 Vested and exercisable as of March 31, 2020 9,176 $ 1.53 6.0 $ 247,727 The aggregate intrinsic value of stock option awards exercised was $31.2 million and $4.2 million for the three months ended March 31, 2020 and 2019 , respectively. Aggregate intrinsic value represents the difference between the exercise price and the fair value of the shares underlying common stock on the date of exercise. No options were granted during the three months ended March 31, 2020 and 2019. As of March 31, 2020 , total unrecognized compensation expense related to unvested stock options, Performance RSUs and restricted stock units granted was $49.8 million , which is expected to be recognized over a weighted-average period of 3.2 years. Options and Restricted Stock Units with Service- and Market-Based Vesting Conditions In March 2019, we canceled stock options with a combination of service- and market-based vesting conditions covering a total of 196,460 shares that were granted in 2018. In January 2019, we granted restricted stock units covering a total of 161,250 shares with a combination of service- and market-based vesting conditions to an executive. We recognized stock-based compensation expense of $0.2 million and $0.4 million for the three months ended March 31, 2020 and 2019 , respectively, in connection with these service- and market-based grants. Additionally, we recognized stock-based compensation expense of $0.2 million related to the canceled market-based options for the three months ended March 31, 2019 . The unrecognized stock-based compensation expense for market-based awards as of March 31, 2020 was $1.4 million , which is expected to be recognized over a weighted-average period of 2.5 years. Restricted Stock Awards Shares Weighted- Average Grant Date Fair Value (in thousands, except per share data) Unvested balance, December 31, 2019 736 $ 9.76 Vested (122 ) $ 9.76 Unvested balance, March 31, 2020 614 $ 9.76 In March 2019, we issued a restricted stock award covering 982,301 shares of our common stock to an executive with a grant date fair value of $9.6 million . We recognized restricted stock awards related stock-based compensation expense of $0.5 million and $0.2 million for the three months ended March 31, 2020 and 2019 , respectively. As of March 31, 2020 , the unrecognized stock-based compensation expense related to these restricted stock awards was $5.0 million , which is expected to be recognized over a weighted-average period of 2.4 years. Restricted Stock Units and Performance Stock Units Restricted Weighted- (in thousands, except per Balance as of December 31, 2019 4,708 $ 11.31 Granted 726 $ 24.41 Released (620 ) $ 8.79 Forfeited (101 ) $ 17.95 Balance as of March 31, 2020 4,713 $ 13.52 Prior to our IPO, we granted restricted stock units that contain both service- and performance-based vesting conditions to our executives, employees and consultants (“Performance RSUs”). The service-based vesting condition is generally satisfied (i) over four years with 25% vesting on the one-year anniversary of the award and the remainder vesting monthly over the next 36 months , or (ii) over four years with 1/48 vesting on the one-month anniversary of the award, and remainder vesting monthly over the next 47 months , subject to the grantee’s continued service with us through the vesting dates. The performance-based vesting condition is satisfied upon the earlier of (i) a change in control where the consideration paid to our equity security holders is cash, publicly traded stock, or a combination of both, or (ii) six months and one day following our IPO. The satisfaction of the performance-based vesting condition became probable upon the completion of our IPO in July 2019, at which point we recorded cumulative stock-based compensation expense using the accelerated attribution method. During the three months ended March 31, 2020, the vesting terms for Performance RSUs were modified from monthly to quarterly basis. The modification had no material impact on our condensed consolidated financial statements. Subsequent to our IPO in July 2019, we grant restricted stock units to our executives, employees and consultants that only contain service-based vesting conditions ("RSUs"). The service-based vesting condition is generally satisfied over four years on a quarterly basis, with each 1/16 vesting on prefixed quarterly vesting anchor dates, subject to the grantee's continued service with us through the vesting dates. In January 2019, we granted restricted stock units covering 982,301 shares to an executive that contain only service-based vesting conditions over a four year period and recognized stock-based compensation expense of $0.5 million and 0.4 million , respectively, during the three months ended March 31, 2020 and 2019. In addition, we granted restricted stock units covering 491,151 shares that immediately vested on the grant date and recognized $3.8 million of stock-based compensation expense in our condensed consolidated statements of operations for the three months ended March 31, 2019. During the three months ended March 31, 2020 and 2019, $6.1 million and $4.2 million stock-based compensation expense related to performance RSUs and RSUs, respectively, was recognized in our condensed consolidated statements of operations. Additionally, included in the shares granted during the three months ended March 31, 2020, we issued performance-based restricted stock units covering 23,196 shares which consist of both service- and performance-based conditions. The service-based vesting condition is satisfied over one year on a quarterly basis from the date the applicable sales milestones are met. The performance-based vesting condition is satisfied upon the achievement of certain sales milestones. In April 2019, we issued other performance-based restricted stock units covering 100,000 shares which consist of both service- and performance-based vesting conditions including both the achievement of certain sales milestones and our IPO. The service-based vesting condition is satisfied over four years from the date the sales milestones were met. The performance-based vesting condition was satisfied upon both the achievement of certain sales milestones and our IPO. Stock-based compensation expense related to these performance-based restricted stock units that are expected to vest was $0.1 million during the three months ended March 31, 2020 . 2019 Employee Stock Purchase Plan In July 2019, our board of directors adopted, and our stockholders approved, our Employee Stock Purchase Plan ("ESPP"). Our ESPP became effective as of the business day immediately prior to the effective date of our IPO. A total of 890,000 shares of our common stock was initially available for sale under our ESPP. In addition, the number of shares available for sale under our ESPP will include an annual increase on the first day of each fiscal year beginning on January 1, 2020, equal to the least of: (i) 2,670,000 shares, (ii) 1% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as our board of directors may determine as of no later than the last day of our immediately preceding fiscal year. Each offering period will be approximately six months in duration commencing on the first trading day on or after May 15 and November 15 of each year and terminating on the first trading day on or after November 15 and May 15 approximately six months later, provided however that the first offering period commenced on the first trading day after our IPO date and will end on May 15, 2020. All regular employees, including executive officers, employed by us or by any of our designated affiliates, except for those holding 5% or more of the total combined voting power or value of our common stock, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, the purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of each offering period or on the purchase date, subject to a limit of the lesser of (i) 500 shares of our common stock, or (ii) $12,500 divided by the fair market value of our common stock as of the first day of the offering period, with any resulting fractional share rounded down to the nearest whole share. As of March 31, 2020 , no shares of common stock have been purchased under our ESPP. During the three months ended March 31, 2020 , we recognized $0.4 million in stock-based compensation expense related to our ESPP in our condensed consolidated statements of operations. As of March 31, 2020 , the unrecognized stock-based compensation expense related to our ESPP is $0.2 million , which is expected to be recognized over a weighted average period of 0.1 year. Award Modifications In March 2020, we accelerated vesting of 11,412 RSUs for terminated employees, resulting in an incremental stock-based compensation expense of $0.1 million recognized in the consolidated statements of operations for the three months ended March 31, 2020. Stock-Based Compensation Expense Stock-based compensation expense in the condensed consolidated statements of operations is summarized as follows: Three Months Ended March 31, 2020 2019 (in thousands) Cost of revenue $ 92 $ 6 Research and development expenses 2,216 361 Sales and marketing expenses 2,052 219 General and administrative expenses 3,703 4,924 Total stock-based compensation expense $ 8,063 $ 5,510 Stock-based compensation costs related to capitalized internal-use software during the three months ended March 31, 2020 was $0.1 million , and less than $0.1 million for the three months ended March 31, 2019.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We recorded an insignificant income tax expense for the three months ended March 31, 2020 , primarily due to state taxes and income taxes on foreign income. The income tax benefit of $1.4 million for the three months ended March 31, 2019 was due to the release of a valuation allowance arising from a deferred tax liability in connection with the myStrength acquisition. The deferred tax liability provided an additional source of taxable income to support the realizability of pre-existing deferred tax assets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted and signed into law. The CARES Act includes a number of income tax changes, including, but not limited to, (i) permitting net operating loss carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (ii) accelerating AMT tax refunds, (iii) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (iv) providing a technical correction for depreciation as relates to qualified improvement property. We have preliminarily evaluated the impact of the CARES Act and do not expect the CARES Act will result in material impact.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to our common stockholders: Three Months Ended March 31, 2020 2019 (in thousands, except per share data) Net loss $ (5,573 ) $ (14,371 ) Accretion of redeemable convertible preferred stock — (41 ) Net loss attributable to common stockholders $ (5,573 ) $ (14,412 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 95,543 18,207 Net loss per share attributable to common stockholders, basic and diluted $ (0.06 ) $ (0.79 ) As we have reported net loss for each of the periods presented, all potentially dilutive securities are antidilutive. The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2020 2019 (in thousands) Redeemable convertible preferred stock — 58,615 Stock options 12,629 16,757 Restricted stock awards subject to repurchase 614 982 Common stock warrants 695 785 Restricted stock units 4,713 982 ESPP obligations 87 — Total anti-dilutive shares 18,738 78,121

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information We operate as one operating segment as we only report financial information on an aggregate and consolidated basis to the Chief Executive Officer, our chief operating decision maker, who regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. There are no segment managers who are held accountable for operations, operating results, and plans for components or types of products or services below the consolidated unit level. As of March 31, 2020 and December 31, 2019 , substantially all of our long-lived assets were located in the United States and all revenue was earned in the United States for the three months ended March 31, 2020 and 2019 .

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions During the three months ended March 31, 2020 , and 2019 , we paid immaterial shared service fees related to financial, legal, and administrative support to a stockholder pursuant to a shared services agreement. We had an employment arrangement with a managing partner of a stockholder. Salary paid under the employment agreement for three months ended March 31, 2019 was not material. No such fees were paid during the three months ended March 31, 2020 . In February 2019, we assumed an additional lease agreement previously held by a stockholder for our Chicago office space with an initial expiration date in December 2024. We entered into a sublease agreement with the stockholder for a portion of the leased space. The sublease term expires in December 2024. Sublease income recorded for this sublease was not material for the three months ended March 31, 2020 and 2019

Employee Benefits

Employee Benefits	3 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits We sponsor a 401(k) plan for employees, which provides for us to make discretionary matching or discretionary annual contributions to the plan. We recognized expense of $0.8 million and $0.4 million for the three months ended March 31, 2020 and 2019 , respectively, related to our 401(k) plan.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies - (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Livongo Health, Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP. The accompanying interim condensed consolidated balance sheets as of March 31, 2020 , the interim condensed consolidated statements of operations and the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three months ended March 31, 2020 and 2019 , and the interim condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. These interim condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, include all adjustments necessary to fairly state our financial position as of March 31, 2020 , the results of our operations for the three months ended March 31, 2020 and 2019 and result of our cash flows for the three months ended March 31, 2020 and 2019 . The financial data and other financial information disclosure in the notes to these interim condensed consolidated financial statements related to the three months periods are also unaudited. The results for the three months ended March 31, 2020 are not necessarily indicative of the operating results expected for the year ending December 31, 2020 or any future period. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 24, 2020. We have revised our condensed consolidated statements of operations and cash flows for the three months ended March 31, 2019 to reflect the adoption of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASC 606, as of January 1, 2019, on a modified retrospective basis. This revision was made because our financial statements presented in our Quarterly Report on Form 10-Q for the period ended March 31, 2019 were prepared in accordance with ASC 605, the prior accounting standard. In addition, we made other adjustments to our financial results for the first quarter through the third quarter of 2019 to correct errors that consist of (i) a $1.9 million total adjustment for the capitalization and amortization of device costs for Livongo for Hypertension and Livongo for Prediabetes and Weight Management, (ii) a $1.2 million total reduction of sales and marketing expenses for the capitalization and amortization of certain sales commissions, and (iii) a $0.4 million increase in sales and marketing expenses. We evaluated the materiality of these revisions, quantitatively and qualitatively, and determined that these revisions were not material to any of our previously issued condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. Such estimates, judgments, and assumptions include: revenue recognition, allowance for doubtful accounts, the period of benefit for deferred commissions, the period of benefit for deferred device costs, estimated costs for capitalized internal-use software, assessment of the useful life and recoverability of long-lived assets, fair values of stock-based awards, contingent consideration in business combinations, the incremental borrowing rate ("IBR") applied in lease accounting, and income taxes. Actual results could be different from these estimates. While the COVID-19 pandemic has not had a material adverse impact on our results of operations to date, our estimates for revenue recognition and allowance for doubtful accounts, as well as our other estimates, judgments, and assumptions, may be materially and adversely different from our actual results as a result of the COVID-19 pandemic. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected.
Emerging Growth Company Status	Emerging Growth Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.
Concentration of Risk	We utilize a limited number of manufacturing vendors to build and assemble our products. The hardware components included in our devices are sourced from various suppliers by the manufacturer and are principally industry standard parts and components that are available from multiple vendors. Quality or performance failures of the glucometer or changes in the contractors’ or vendors’ financial or business condition could disrupt our ability to supply quality products to our clients and thereby have a material adverse impact on our business, financial condition and results of operations. Concentration of Risk Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, certificates of deposit, and accounts receivable. We maintain our cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. We invest our cash equivalents in highly rated money market funds and short-term investments in certificates of deposit. We have not experienced any losses in such accounts. We believe we are not exposed to any significant credit risk on cash, cash equivalents, investments and restricted cash and perform periodic evaluations of the credit standing of such institutions. Our sales are predominately to self-insured employers, healthcare providers, and insurance carriers located throughout North America. Accounts receivable are recorded at the invoiced amount, and are stated at realizable value, net of an allowance for doubtful accounts. We perform ongoing assessments of our clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. We have not experienced material credit losses from our accounts receivable.
Recent Accounting Pronouncements Adopted and New Account Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Adopted in Fiscal 2020 Leases: In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance (collectively, "ASC 842"), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU is effective for us for the interim periods and year ending December 31, 2020. Early adoption is permitted. We adopted ASC 842 on January 1, 2020 using the modified retrospective approach by electing to use the optional transition method which allows us to continue to apply the previous guidance, including disclosure requirements, in the comparative periods presented. We elected to use certain practical expedients permitted under the transition guidance within the new guidance, which allows us to carry forward the historical accounting relating to lease identification and classification for existing leases upon adoption. We also elected not to use the hindsight practical expedient in determining the lease term and impairment of the operating lease right-of-use ("ROU") assets and elected not to record operating leases with an initial term of 12 months or less on our condensed consolidated balance sheets. We elected not to separate lease and non-lease components for all classes of underlying assets. Adoption of the new lease standard resulted in the recording of ROU assets and operating lease liabilities of approximately $18.1 million and $18.6 million , respectively, as of January 1, 2020. The difference between the ROU assets and operating lease liabilities primarily relates to deferred rent of $0.5 million recorded in accordance with the previous lease guidance. The adoption had no impact on total cash flows from operations other than a change within operating cash flows. We determine if an arrangement is or contains a lease at inception. Our lease agreements do not contain any material options to extend or terminate leases, any material residual value guarantees, any material restrictions or covenants, or any material variable lease payments. Any variable lease payments consist of common area maintenance, taxes and other costs and are expensed as incurred. We have performed an evaluation of our other contracts with customers and suppliers in accordance with ASC 842 and have determined that, none of our other contracts contain a lease. ROU assets represent our right to use an underlying asset for the lease term, while operating lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. In determining the present value of lease payments, we use our IBR based on the information available at the lease commencement date, including the lease term, for operating leases. The incremental borrowing rate is a hypothetical rate based on our understanding of what our credit rating would be for a secured borrowing in the country where the lease was executed. Upon adoption, the ROU asset was valued at the amount of the operating lease liabilities adjusted for lease incentives, prepaid rent, and deferred rent as of January 1, 2020. The adoption of the new standard resulted in changes to our accounting policies for leases and in additional disclosures. See Note 8. Stock-Based Compensation: In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . The standard simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. ASU No. 2018-07 is effective for us for the interim periods and the year beginning January 1, 2020. Early adoption is permitted. We adopted this new standard using a prospective method on January 1, 2020. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. Disclosure of Fair Value Measurement: In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including interim reporting periods within those fiscal years. ASU 2018-13 is effective for us for the interim periods and the year beginning January 1, 2020. We adopted the new standard using a prospective method effective on January 1, 2020. The adoption of this ASU resulted in additional disclosures in Note 6 of our condensed consolidated financial statements. New Accounting Pronouncements Not Yet Adopted Credit Losses: In June 2018, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard requires a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected, with further clarifications made more recently. For trade receivables, loans, and other financial assets, we will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available-for-sale debt securities are required to be recorded through an allowance for credit losses rather than a reduction in the amortized cost basis of the securities. This new standard is effective for us for the interim periods within and the year ending December 31, 2020. Early adoption is permitted. We are currently evaluating the impact of this ASU on our consolidated financial statements. Cloud Computing Arrangements Implementation Costs : In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. This ASU is effective for us for the year ending December 31, 2021, and interim periods within the year ending December 31, 2022. Early adoption is permitted. This standard could be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact of this ASU on our consolidated financial statements and expect to apply this standard using the prospective transition method. Income Taxes : In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies that accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amending existing guidance to improve consistent application. This new standard is effective for our interim periods and year beginning January 1, 2022. Early adoption is permitted. Most amendments within this standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedules of Concentration Risk	For each significant partner that represented 10% or more of our accounts receivable balance or revenue during the periods presented, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended March 31, March 31, December 31, 2020 2019 2020 2019 Partner A 24 % 25 % 20 % 23 % Partner B 18 % 23 % 22 % 25 %

Revenue, Deferred Revenue and D

Revenue, Deferred Revenue and Deferred Costs and Other (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	Deferred revenue activity is as follows (in thousands): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 4,599 $ 2,051 Amounts billed but unrecognized 3,140 1,378 Revenue recognized (1,640 ) (1,309 ) Assumed from business combination — 1,407 Balance at end of period $ 6,099 $ 3,527 Balance at the end of period (in thousands): March 31, December 31, 2020 2019 Deferred revenue, current $ 5,351 $ 3,945 Deferred revenue, noncurrent 748 654 Total deferred revenue $ 6,099 $ 4,599 Balance at the end of period (in thousands): March 31, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 20,961 $ 1,162 $ 472 $ 22,595 Deferred costs, noncurrent 8,789 1,706 — 10,495 Total deferred costs $ 29,750 $ 2,868 $ 472 $ 33,090 December 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 14,746 $ 1,121 $ 184 $ 16,051 Deferred costs, noncurrent 3,833 1,867 — 5,700 Total deferred costs $ 18,579 $ 2,988 $ 184 $ 21,751 The activity is as follows (in thousands): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 1,152 $ 609 ASC 606 adoption date impact adjustment — (222 ) Amount deferred 776 193 Revenue recognized (198 ) (2 ) Payments — (45 ) Balance at end of period $ 1,730 $ 533 Deferred costs and other activity is as follows (in thousands): Three Months Ended March 31, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 18,579 $ 2,988 $ 184 $ 21,751 Additions 17,144 174 418 17,736 Revenue recognized — — (130 ) (130 ) Cost of revenue recognized (5,973 ) — — (5,973 ) Sales and marketing expenses recognized — (294 ) — (294 ) Balance at end of period $ 29,750 $ 2,868 $ 472 $ 33,090 Three Months Ended March 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 8,469 $ — $ — $ 8,469 ASC 606 adoption date impact adjustment — 3,692 771 4,463 Additions 8,495 — 112 8,607 Revenue recognized — — (245 ) (245 ) Cost of revenue recognized (2,598 ) — — (2,598 ) Sales and marketing expenses recognized — (254 ) — (254 ) Balance at end of period $ 14,366 $ 3,438 $ 638 $ 18,442

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Schedule of Allocation of Purchase Consideration	The purchase consideration of $33.5 million was allocated as follows: Amount (in thousands) Cash and cash equivalents $ 2,643 Accounts receivable 1,337 Other current assets 140 Property and equipment 114 Intangible assets 13,900 Other assets 34 Total assets acquired 18,168 Accounts payable 173 Accrued expenses and other liabilities 1,787 Deferred revenue 1,407 Deferred tax liability, net 1,396 Total liabilities assumed 4,763 Goodwill 20,092 Total purchase consideration $ 33,497
Components of Identifiable Intangible Assets Acquired and Their Estimated Useful Lives	The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of the acquisition date: Cost Useful Life (in thousands) (years) Customer relationships $ 4,300 7.0 Developed technology 9,200 7.0 Trade name 400 5.0 Total $ 13,900
Schedule of Pro Forma Information	The following unaudited pro forma information presents the combined results of operations as if the myStrength Acquisition had been completed on January 1, 2018, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of myStrength that was not acquired; (ii) amortization of the acquired intangible assets; (iii) fair value adjustment for deferred revenue; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments. March 31, 2019 (in thousands) Revenue $ 32,666 Net loss $ (13,031 )

Balance Sheet Components - (Ta

Balance Sheet Components - (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: March 31, December 31, 2020 2019 (in thousands) Prepaid expenses $ 7,170 $ 6,691 Escrow deposit, current 5,342 2,100 Interest receivable 606 504 Prepaid rent 263 352 Short-term deposits 484 201 Other current assets 4 12 Total $ 13,869 $ 9,860
Property and Equipment, Net	Property and equipment consisted of the following: March 31, December 31, 2020 2019 (in thousands) Computer, equipment and software $ 3,442 $ 2,218 Furniture and fixtures 1,463 915 Capitalized internal-use software 12,545 11,229 Leasehold improvements 1,664 1,092 Property and equipment 19,114 15,454 Less: accumulated depreciation (6,279 ) (5,100 ) Property and equipment, net $ 12,835 $ 10,354
Schedule of Intangible Assets, Net	Intangible assets consisted of the following as of March 31, 2020 : Gross Value Accumulated Amortization Net Book Value Weighted- Average Remaining Useful Life (in thousands) (years) Customer relationships $ 8,190 $ (1,479 ) $ 6,711 6.8 Developed technology 11,020 (2,268 ) 8,752 5.4 Trade name 448 (138 ) 310 3.8 Total $ 19,658 $ (3,885 ) $ 15,773 Intangible assets consisted of the following as of December 31, 2019 : Gross Value Accumulated Amortization Net Book Value Weighted- Average Remaining Useful Life (in thousands) (years) Customer relationships $ 8,190 $ (1,227 ) $ 6,963 7.1 Developed technology 11,020 (1,848 ) 9,172 5.7 Trade names 448 (114 ) 334 4.0 Total $ 19,658 $ (3,189 ) $ 16,469
Finite-lived Intangible Assets Amortization Expense	Amortization expense for intangible assets for the three months ended March 31, 2020 and 2019 is as follows: Three Months Ended March 31, 2020 2019 (in thousands) Customer relationships $ 252 $ 209 Developed technology 420 327 Trade names 24 28 Total $ 696 $ 564
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The expected future amortization expense related to intangible assets as of March 31, 2020 was as follows: Amount (in thousands) Remainder of 2020 $ 2,073 2021 2,762 2022 2,750 2023 2,494 2024 2,324 Thereafter 3,370 Total $ 15,773
Schedule of Noncurrent Other Assets	Other noncurrent assets consisted of the following: March 31, December 31, 2020 2019 (in thousands) Escrow deposit, noncurrent $ — $ 3,150 Other 215 310 Total $ 215 $ 3,460
Schedule of Accrued Liabilities and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: March 31, December 31, 2020 2019 (in thousands) Accrued bonus $ 3,304 $ 8,652 Vendor accruals 4,305 3,984 Contingent consideration, current 2,915 3,004 Accrued commissions 3,046 2,611 Accrued payroll and employee benefits 2,545 2,291 Accrued sales and use taxes 194 932 Accrued rebates 1,730 1,152 Employee contribution to ESPP 2,303 1,805 Operating lease liabilities, current 2,877 — Other accrued expenses 5,849 3,370 Total $ 29,068 $ 27,801

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities by Level within the Fair Value Hierarchy	The following table sets forth the fair value of our financial assets and liabilities by level within the fair value hierarchy: March 31, 2020 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 105,566 $ — $ — $ 105,566 Short-term investment: Certificate of deposit 150,000 — 150,000 Total assets at fair value $ 255,566 $ — $ — $ 255,566 Liabilities Other current liabilities—contingent consideration $ — $ — $ 2,915 $ 2,915 Total liabilities at fair value $ — $ — $ 2,915 $ 2,915 December 31, 2019 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 130,640 $ — $ — $ 130,640 Short-term investment: Certificate of deposit $ 150,000 $ — $ — $ 150,000 Total assets at fair value $ 280,640 $ — $ — $ 280,640 Liabilities Other current liabilities—contingent consideration $ — $ — $ 3,004 $ 3,004 Other noncurrent liabilities—contingent consideration — — 2,411 2,411 Total liabilities at fair value $ — $ — $ 5,415 $ 5,415
Schedule of Investments Reconciliation	Cash, cash equivalents and short-term investments were as follows (in thousands): March 31, 2020 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 112,662 $ — $ — $ 112,662 Money market funds 105,566 — $ — 105,566 Total cash, and cash equivalents 218,228 — — 218,228 Certificate of deposit 150,000 — — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 368,228 $ — $ — $ 368,228 December 31, 2019 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 111,098 $ — $ — $ 111,098 Money market funds 130,640 — — 130,640 Total cash, and cash equivalents 241,738 — — 241,738 Certificate of deposit 150,000 — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 391,738 $ — $ — $ 391,738
Schedule of Changes in Level 3 Financial Liability	The following table sets forth the changes in our Level 3 financial liabilities for the periods presented: Three Months Ended March 31, 2020 2019 (in thousands) Beginning balance $ 5,415 $ 5,004 Contingent consideration recorded upon acquisition (Note 4) — 3,300 Change in fair value of contingent consideration (Note 4) 84 674 Payment related to myStrength contingent consideration (Note 4) (2,584 ) — Ending balance $ 2,915 $ 8,978

Operating Lease Liabilities (Ta

Operating Lease Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Assets and Liabilities, Lessee	A summary of supplemental lease information is as follows: Three Months Ended March 31, 2020 (in thousands) Weighted average remaining lease term (years) 4.6 Weighted average discount rate 3.8 %
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments, net of future sublease income of $0.2 million , under operating leases as of December 31, 2019 under ASC 840, the prior lease standard, were as follows: Net Minimum Lease Payments (in thousands) 2020 $ 3,908 2021 5,055 2022 5,233 2023 5,141 2024 1,756 Thereafter 3,068 Total future minimum payments $ 24,161 Maturities of operating lease liabilities as of March 31, 2020 are as follows: March 31, 2020 (in thousands) Years ending December 31, 2020 (remaining 9 months) $ 3,391 2021 5,094 2022 5,242 2023 5,213 2024 1,799 2025 and thereafter 3,071 Total lease payments 23,810 Less: imputed interest (2,149 ) Less: tenant allowance (3,308 ) Total operating lease liabilities $ 18,353 Reported as: Operating lease liabilities, current (1) $ 2,877 Operating lease liabilities, noncurrent 15,476 Total operating lease liabilities $ 18,353 (1) Included as part of "Accrued expenses and other current liabilities" on the condensed consolidated balance sheets.

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Shares of Common Stock Reserved for Future Issuance	As of March 31, 2020 and December 31, 2019 , we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: March 31, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 12,629 14,020 Outstanding restricted stock units 4,713 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,843 890 Available for future issuance under 2019 Plan 11,866 8,160 Total 32,360 29,709

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Warrants Outstanding	Common stock warrants outstanding as of March 31, 2020 and December 31, 2019 are as follows: Holder Issue Date Outstanding Shares Exercise Price Exercisable Shares Expiration Date (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Shares Available for Grant and Stock Option Activity	Stock option activity under the Plans is as follows: Options Outstanding Shares Available for Grant Shares Subject to Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands, except per share data and years) Balance as of December 31, 2019 8,160 14,020 $ 1.85 6.7 $ 325,474 Shares authorized 3,812 — Exercised — (1,247 ) $ 1.38 Forfeited/cancelled 144 (144 ) $ 1.88 Restricted stock units and PSUs granted (726 ) — Restricted stock units and PSUs forfeited 101 — Restricted stock units and PSUs withheld for income taxes 375 — Balance as of March 31, 2020 11,866 12,629 $ 1.89 6.4 $ 336,424 Vested and exercisable as of March 31, 2020 9,176 $ 1.53 6.0 $ 247,727
Schedule of Restricted Stock Awards	Restricted Stock Awards Shares Weighted- Average Grant Date Fair Value (in thousands, except per share data) Unvested balance, December 31, 2019 736 $ 9.76 Vested (122 ) $ 9.76 Unvested balance, March 31, 2020 614 $ 9.76
Schedule of Restricted Stock Units	Restricted Weighted- (in thousands, except per Balance as of December 31, 2019 4,708 $ 11.31 Granted 726 $ 24.41 Released (620 ) $ 8.79 Forfeited (101 ) $ 17.95 Balance as of March 31, 2020 4,713 $ 13.52
Summary of Stock-Based Compensation Expense	Stock-based compensation expense in the condensed consolidated statements of operations is summarized as follows: Three Months Ended March 31, 2020 2019 (in thousands) Cost of revenue $ 92 $ 6 Research and development expenses 2,216 361 Sales and marketing expenses 2,052 219 General and administrative expenses 3,703 4,924 Total stock-based compensation expense $ 8,063 $ 5,510

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per share attributable to our common stockholders: Three Months Ended March 31, 2020 2019 (in thousands, except per share data) Net loss $ (5,573 ) $ (14,371 ) Accretion of redeemable convertible preferred stock — (41 ) Net loss attributable to common stockholders $ (5,573 ) $ (14,412 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 95,543 18,207 Net loss per share attributable to common stockholders, basic and diluted $ (0.06 ) $ (0.79 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2020 2019 (in thousands) Redeemable convertible preferred stock — 58,615 Stock options 12,629 16,757 Restricted stock awards subject to repurchase 614 982 Common stock warrants 695 785 Restricted stock units 4,713 982 ESPP obligations 87 — Total anti-dilutive shares 18,738 78,121

Organization and Description _2

Organization and Description of Business - Narrative (Details) $ / shares in Units, $ in Thousands	Jun. 27, 2019	Jul. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018shares
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding (in shares) | shares		58,615,488	0	58,615,000	0	58,615,000
Stock converted		$ 237,000
Accumulated deficit			$ (169,771)		$ (164,198)
Net loss			(5,573)	$ (14,371)
Net cash used in operating activities			$ (10,411)	$ (25,187)
IPO
Class of Stock [Line Items]
Sale of stock (in shares) | shares		14,590,050
Offering price (in dollars per share) | $ / shares		$ 28
Net proceeds from sale of stock		$ 377,500
Underwriting discounts and commissions		28,600
Offering expenses		$ 2,400
Underwriters' Option
Class of Stock [Line Items]
Sale of stock (in shares) | shares		1,903,050
Common Stock
Class of Stock [Line Items]
Stock converted (in shares) | shares		58,615,488
Reverse stock split conversion ratio	0.5
Redeemable convertible preferred stock
Class of Stock [Line Items]
Reverse stock split conversion ratio	0.5
Additional Paid-in Capital
Class of Stock [Line Items]
Stock converted		$ 236,900
Common Stock
Class of Stock [Line Items]
Stock converted		$ 100

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	Sep. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Jan. 01, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing		$ 27,655,000	$ 14,643,000
Other comprehensive loss		0	$ 0
Operating lease right-of-use assets		17,189,000
Total operating lease liabilities		$ 18,353,000
Deferred rent						$ 500,000
Adjustment for Capitalization and Amortization of Sales Commissions
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing				$ (1,200,000)
Increase in Selling and Marketing Expense
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing				400,000
Livongo for Hypertension and Livongo for Prediabetes and Weight Management | Adjustment for Capitalization and Amortization of Device Costs
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Capitalized device costs	$ 1,900,000			$ 1,900,000
Amortization	$ 1,900,000
Accounting Standards Update 2016-02
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating lease right-of-use assets					$ 18,100,000
Total operating lease liabilities					$ 18,600,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Partner Concentration Risk	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Partner A | Revenue
Concentration Risk [Line Items]
Concentration risk percentage			24.00%	25.00%
Partner A | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	20.00%	23.00%
Partner B | Revenue
Concentration Risk [Line Items]
Concentration risk percentage			18.00%	23.00%
Partner B | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	22.00%	25.00%

Revenue, Deferred Revenue and_2

Revenue, Deferred Revenue and Deferred Costs and Other - Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Change in Contract with Customer, Liability [Abstract]
Balance at beginning of period	$ 4,599	$ 2,051
Amounts billed but unrecognized	3,140	1,378
Revenue recognized	(1,640)	(1,309)
Assumed from business combination	0	1,407
Balance at end of period	6,099	3,527
Deferred revenue, current			$ 5,351	$ 3,945
Deferred revenue, noncurrent			748	654
Total deferred revenue	$ 4,599	$ 3,527	$ 6,099	$ 4,599

Revenue, Deferred Revenue and_3

Revenue, Deferred Revenue and Deferred Costs and Other - Revenue Performance Obligation (Details) $ in Millions	Mar. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue to be recognized	$ 5.4
Timing for recognition of deferred revenue	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue to be recognized	$ 0.7
Timing for recognition of deferred revenue

Revenue, Deferred Revenue, an_2

Revenue, Deferred Revenue, and Deferred Costs and Other Revenue, Deferred Revenue, and Deferred Costs and Other - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Accrued rebates	$ 1,730	$ 1,152	$ 533	$ 609

Revenue, Deferred Revenue and_4

Revenue, Deferred Revenue and Deferred Costs and Other - Accrued Rebates (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jan. 01, 2019
Change In Accrued Rebate [Roll Forward]
Balance at beginning of period	$ 1,152	$ 609
ASC 606 adoption date impact adjustment	1,730	533
Amount deferred	776	193
Revenue recognized	(198)	(2)
Payments	0	(45)
Balance at end of period	$ 1,730	$ 533
Impact of Adoption | ASC 606
Change In Accrued Rebate [Roll Forward]
ASC 606 adoption date impact adjustment			$ (222)

Revenue, Deferred Revenue and_5

Revenue, Deferred Revenue and Deferred Costs and Other - Deferred Costs and Other (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	$ 21,751	$ 8,469
ASC 606 adoption date impact adjustment	21,751	18,442	$ 33,090	$ 21,751
Additions	17,736	8,607
Revenue recognized	(130)	(245)
Cost of revenue recognized	(5,973)	(2,598)
Sales and marketing expenses recognized	(294)	(254)
Balance at end of period	33,090	18,442
Deferred costs, current			22,595	16,051
Deferred costs, noncurrent			10,495	5,700
Total deferred costs	21,751	18,442	33,090	21,751
Deferred Device Costs
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	18,579	8,469
ASC 606 adoption date impact adjustment	29,750	14,366	29,750	18,579
Additions	17,144	8,495
Revenue recognized	0	0
Cost of revenue recognized	(5,973)	(2,598)
Sales and marketing expenses recognized	0	0
Balance at end of period	29,750	14,366
Deferred costs, current			20,961	14,746
Deferred costs, noncurrent			8,789	3,833
Total deferred costs	29,750	14,366	29,750	18,579
Deferred Contract Costs
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	2,988	0
ASC 606 adoption date impact adjustment	2,988	3,438	2,868	2,988
Additions	174	0
Revenue recognized	0	0
Cost of revenue recognized	0	0
Sales and marketing expenses recognized	(294)	(254)
Balance at end of period	2,868	3,438
Deferred costs, current			1,162	1,121
Deferred costs, noncurrent			1,706	1,867
Total deferred costs	2,988	3,438	2,868	2,988
Deferred Execution Credits
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	184	0
ASC 606 adoption date impact adjustment	184	638	472	184
Additions	418	112
Revenue recognized	(130)	(245)
Cost of revenue recognized	0	0
Sales and marketing expenses recognized	0	0
Balance at end of period	472	638
Deferred costs, current			472	184
Deferred costs, noncurrent			0	0
Total deferred costs	$ 184	$ 638	$ 472	$ 184
Impact of Adoption | ASC 606
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment					$ 4,463
Total deferred costs					4,463
Impact of Adoption | ASC 606 | Deferred Device Costs
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment					0
Total deferred costs					0
Impact of Adoption | ASC 606 | Deferred Contract Costs
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment					3,692
Total deferred costs					3,692
Impact of Adoption | ASC 606 | Deferred Execution Credits
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment					771
Total deferred costs					$ 771

Business Combinations - Narrati

Business Combinations - Narrative (Details) - USD ($)	1 Months Ended				3 Months Ended
	Dec. 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Apr. 30, 2018	Mar. 31, 2020	Mar. 31, 2019
Business Acquisition [Line Items]
Increase (decrease) in fair value of contingent consideration					$ 84,000	$ 674,000
Payment of deferred acquisition-related contingent consideration					884,000	0
Retrofit
Business Acquisition [Line Items]
Total purchase consideration paid in cash				$ 12,400,000
Earn-out consideration obligated to pay (up to)				7,000,000
Escrow asset				7,000,000
Fair value of contingent consideration				6,200,000
Total purchase consideration				$ 18,600,000
Increase (decrease) in fair value of contingent consideration					100,000
Escrow deposit disbursements		$ 1,800,000
Contingent consideration	$ 2,800,000				2,900,000
myStrength
Business Acquisition [Line Items]
Total purchase consideration paid in cash			$ 30,100,000
Earn-out consideration obligated to pay (up to)			5,000,000
Fair value of contingent consideration			3,300,000
Total purchase consideration			33,500,000
Increase (decrease) in fair value of contingent consideration						600,000
Closing adjustment			$ 100,000
Payment of deferred acquisition-related contingent consideration	$ 2,400,000				2,600,000
Acquisition-related costs					$ 200,000
Former Retrofit Stockholders | Retrofit
Business Acquisition [Line Items]
Escrow deposit disbursements		$ 1,300,000
Maximum | Retrofit
Business Acquisition [Line Items]
Increase (decrease) in fair value of contingent consideration						$ 100,000

Business Combinations - Schedul

Business Combinations - Schedule of Allocation of Purchase Consideration (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Feb. 28, 2019
Business Acquisition [Line Items]
Goodwill	$ 35,801	$ 35,801
myStrength
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2,643
Accounts receivable			1,337
Other current assets			140
Property and equipment			114
Acquired intangible assets			13,900
Other assets			34
Total assets acquired			18,168
Accounts payable			173
Accrued expenses and other liabilities			1,787
Deferred revenue			1,407
Deferred tax liability, net			1,396
Liabilities assumed			4,763
Goodwill			20,092
Total purchase consideration			$ 33,497

Business Combinations - Compone

Business Combinations - Components of Identifiable Intangible Assets Acquired and Their Estimated Useful Lives (Details) - myStrength $ in Thousands	1 Months Ended
	Feb. 28, 2019USD ($)
Business Acquisition [Line Items]
Cost	$ 13,900
Customer relationships
Business Acquisition [Line Items]
Cost	$ 4,300
Useful Life	7 years
Developed technology
Business Acquisition [Line Items]
Cost	$ 9,200
Useful Life	7 years
Trade name
Business Acquisition [Line Items]
Cost	$ 400
Useful Life	5 years

Business Combinations - Sched_2

Business Combinations - Schedule of Pro Forma Information (Details) - myStrength $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Business Acquisition [Line Items]
Revenue	$ 32,666
Net loss	$ (13,031)

Balance Sheet Components - Inv

Balance Sheet Components - Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 19.2	$ 29

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses	$ 7,170	$ 6,691
Escrow deposit, current	5,342	2,100
Interest receivable	606	504
Prepaid rent	263	352
Short-term deposits	484	201
Other current assets	4	12
Total	$ 13,869	$ 9,860

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment	$ 19,114		$ 15,454
Less: accumulated depreciation	(6,279)		(5,100)
Property and equipment, net	12,835		10,354
Depreciation and amortization expense	1,180	$ 696
Computer, equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	3,442		2,218
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	1,463		915
Capitalized internal-use software
Property, Plant and Equipment [Line Items]
Property and equipment	12,545		11,229
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,664		$ 1,092

Balance Sheet Components - Inta

Balance Sheet Components - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 19,658	$ 19,658
Accumulated Amortization	(3,885)	(3,189)
Net Book Value	15,773	16,469
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Value	8,190	8,190
Accumulated Amortization	(1,479)	(1,227)
Net Book Value	6,711	6,963
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Value	11,020	11,020
Accumulated Amortization	(2,268)	(1,848)
Net Book Value	8,752	9,172
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Value	448	448
Accumulated Amortization	(138)	(114)
Net Book Value	$ 310	$ 334
Weighted Average | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	6 years 9 months 18 days	7 years 1 month 6 days
Weighted Average | Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	5 years 4 months 24 days	5 years 8 months 12 days
Weighted Average | Trade name
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	3 years 9 months 18 days	4 years

Balance Sheet Components - In_2

Balance Sheet Components - Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 696	$ 564
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	252	209
Developed technology
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	420	327
Trade name
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 24	$ 28

Balance Sheet Components - Futu

Balance Sheet Components - Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remainder of 2020	$ 2,073
2021	2,762
2022	2,750
2023	2,494
2024	2,324
Thereafter	3,370
Net Book Value	$ 15,773	$ 16,469

Balance Sheet Components - Good

Balance Sheet Components - Goodwill (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Goodwill	$ 35,801,000	$ 35,801,000
Goodwill impairment	$ 0

Balance Sheet Components - Othe

Balance Sheet Components - Other Noncurrent Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Escrow deposit, noncurrent	$ 0	$ 3,150
Other	215	310
Total	$ 215	$ 3,460

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued bonus	$ 3,304	$ 8,652
Vendor accruals	4,305	3,984
Contingent consideration, current	2,915	3,004
Accrued commissions	3,046	2,611
Accrued payroll and employee benefits	2,545	2,291
Accrued sales and use taxes	194	932
Accrued rebates	1,730	1,152
Employee contribution to ESPP	2,303	1,805
Operating lease liabilities, current	2,877
Other accrued expenses	5,849	3,370
Total	$ 29,068	$ 27,801

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities by Level within the Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets
Cash equivalents and short-term investments	$ 218,228	$ 241,738
Liabilities
Other current liabilities—contingent consideration	2,915	3,004
Fair Value, Recurring
Assets
Total assets at fair value	255,566	280,640
Liabilities
Other current liabilities—contingent consideration	2,915	3,004
Other noncurrent liabilities—contingent consideration		2,411
Total liabilities at fair value	2,915	5,415
Fair Value, Recurring | Level 1
Assets
Total assets at fair value	255,566	280,640
Liabilities
Other current liabilities—contingent consideration	0	0
Other noncurrent liabilities—contingent consideration		0
Total liabilities at fair value	0	0
Fair Value, Recurring | Level 2
Assets
Total assets at fair value	0	0
Liabilities
Other current liabilities—contingent consideration	0	0
Other noncurrent liabilities—contingent consideration		0
Total liabilities at fair value	0	0
Fair Value, Recurring | Level 3
Assets
Total assets at fair value	0	0
Liabilities
Other current liabilities—contingent consideration	2,915	3,004
Other noncurrent liabilities—contingent consideration		2,411
Total liabilities at fair value	2,915	5,415
Money market funds
Assets
Cash equivalents and short-term investments	105,566	130,640
Money market funds | Fair Value, Recurring
Assets
Cash equivalents and short-term investments	105,566	130,640
Money market funds | Fair Value, Recurring | Level 1
Assets
Cash equivalents and short-term investments	105,566	130,640
Money market funds | Fair Value, Recurring | Level 2
Assets
Cash equivalents and short-term investments	0	0
Money market funds | Fair Value, Recurring | Level 3
Assets
Cash equivalents and short-term investments	0	0
Certificate of deposit | Fair Value, Recurring
Assets
Cash equivalents and short-term investments	150,000	150,000
Certificate of deposit | Fair Value, Recurring | Level 1
Assets
Cash equivalents and short-term investments	150,000	150,000
Certificate of deposit | Fair Value, Recurring | Level 2
Assets
Cash equivalents and short-term investments		0
Certificate of deposit | Fair Value, Recurring | Level 3
Assets
Cash equivalents and short-term investments	$ 0	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Unrealized Gains (Losses) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Adjusted Amortized Cost
Cash and cash equivalents	$ 218,228	$ 241,738	$ 54,996
Certificate of deposit	150,000	150,000
Total cash, cash equivalents and short-term investments	368,228	391,738
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value
Cash equivalents and cash equivalents, fair value	218,228	241,738
Total cash, and cash equivalents	150,000	150,000
Total cash, cash equivalents and short-term investments	368,228	391,738
Cash
Adjusted Amortized Cost
Cash and cash equivalents	112,662	111,098
Fair Value
Cash equivalents and cash equivalents, fair value	112,662	111,098
Money market funds
Adjusted Amortized Cost
Cash and cash equivalents	105,566	130,640
Fair Value
Cash equivalents and cash equivalents, fair value	105,566	130,640
Certificate of deposit
Adjusted Amortized Cost
Certificate of deposit	150,000	150,000
Gross Unrealized Gains	0
Gross Unrealized Losses	0	0
Fair Value
Total cash, and cash equivalents	$ 150,000	$ 150,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration liability	$ 2,915	$ 5,415	$ 8,978	$ 5,004
Measurement Input, Revenue Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.0382
Measurement Input, Revenue Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.006
Measurement Input, Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.0017

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Changes in Level 3 Financial Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5,415	$ 5,004
Contingent consideration recorded upon acquisition (Note 4)	0	3,300
Change in fair value of contingent consideration (Note 4)	84	674
Payment related to myStrength contingent consideration (Note 4)	(2,584)	0
Ending balance	$ 2,915	$ 8,978

Revolving Loan - Narrative (De

Revolving Loan - Narrative (Details) - Revolving Credit Facility - Line of Credit - USD ($)	1 Months Ended
	Jul. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Aggregate principal amount of secured revolving loan facility	$ 30,000,000
Floor interest rate	5.25%
Loans outstanding		$ 0	$ 0
Prime Rate
Debt Instrument [Line Items]
Floating interest rate	0.25%

Operating Lease Liabilities -

Operating Lease Liabilities - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 1.1
Variable lease cost	0.2
Rent expense		$ 0.6
Future sublease income receivable	$ 0.2
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	3 years
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	7 years

Operating Lease Liabilities - S

Operating Lease Liabilities - Supplemental Lease Information (Details)	Mar. 31, 2020
Leases [Abstract]
Weighted average remaining lease term (years)	4 years 7 months 6 days
Weighted average discount rate	3.80%

Operating Lease Liabilities - O

Operating Lease Liabilities - Operating Lease Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating Leases After Adoption
2020 (remaining 9 months)	$ 3,391
2021	5,094
2022	5,242
2023	5,213
2024	1,799
2025 and thereafter	3,071
Total lease payments	23,810
Less: imputed interest	(2,149)
Less: tenant allowance	(3,308)
Total operating lease liabilities	18,353
Operating lease liabilities, current	2,877
Operating lease liabilities, noncurrent	15,476
Total operating lease liabilities	$ 18,353
Operating Leases Before Adoption
2020		$ 3,908
2021		5,055
2022		5,233
2023		5,141
2024		1,756
Thereafter		3,068
Total future minimum payments		$ 24,161

Stockholders_ Equity - Narrativ

Stockholders’ Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Dec. 31, 2019	Jul. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Class of Stock [Line Items]
Stock converted		$ 237,000
Accretion to redemption price of redeemable convertible preferred stock (less than for the three months ended June 30, 2019 and 2018)			$ 0	$ 41
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	900,000,000	900,000,000	900,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
IPO
Class of Stock [Line Items]
Sale of stock (in shares)		14,590,050
Offering price (in dollars per share)		$ 28
Net proceeds from sale of stock		$ 377,500
Underwriting discounts and commissions		28,600
Offering expenses		$ 2,400
Underwriters' Option
Class of Stock [Line Items]
Sale of stock (in shares)		1,903,050
Common Stock
Class of Stock [Line Items]
Stock converted (in shares)		58,615,488
Common Stock | Secondary Offering - Shares From Existing Shareholders [Member]
Class of Stock [Line Items]
Sale of stock (in shares)	2,777,327
Offering price (in dollars per share)	$ 27
Maximum
Class of Stock [Line Items]
Accretion to redemption price of redeemable convertible preferred stock (less than for the three months ended June 30, 2019 and 2018)				$ 100

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details) - shares shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Total	32,360	29,709
Outstanding options to purchase common stock
Class of Stock [Line Items]
Total	12,629	14,020
Outstanding restricted stock units
Class of Stock [Line Items]
Total	4,713	5,208
Restricted stock awards subject to repurchase
Class of Stock [Line Items]
Total	614	736
Estimated shares for future ESPP purchase
Class of Stock [Line Items]
Total	1,843	890
Available for future issuance under 2019 Plan
Class of Stock [Line Items]
Total	11,866	8,160
Outstanding warrants to purchase common stock
Class of Stock [Line Items]
Total	695	695

Common Stock Warrants - Schedu

Common Stock Warrants - Schedule of Warrants Outstanding (Details) shares in Thousands	Mar. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Outstanding shares (in shares)	695
Exercisable shares (in shares)	695
Warrants Expiring Feb 2025
Class of Warrant or Right [Line Items]
Outstanding shares (in shares)	695
Exercise price (in dollars per share) | $ / shares	$ 2.28
Exercisable shares (in shares)	695

Common Stock Warrants - Narrati

Common Stock Warrants - Narrative (Details)	3 Months Ended
	Mar. 31, 2020shares
Equity [Abstract]
Warrants exercised (in shares)	0

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	1 Months Ended					3 Months Ended
	Mar. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	32,360,000					32,360,000		29,709,000
Aggregate intrinsic value of stock option awards exercised						$ 31,200,000	$ 4,200,000
Options granted (in shares)						0
Unrecognized compensation expense	$ 49,800,000					$ 49,800,000
Unrecognized compensation expense, recognition period						3 years 2 months 12 days
Stock-based compensation expense						$ 8,063,000	5,510,000
Stock-based compensation related to capitalized internal-use software (less than)						$ 100,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	614,000					614,000		736,000
Unrecognized compensation expense	$ 5,000,000					$ 5,000,000
Unrecognized compensation expense, recognition period						2 years 4 months 24 days
Number of awards granted (in shares)				982,301
Grant date fair value of awards issued				$ 9,600,000
Stock-based compensation expense						$ 500,000	200,000
Vested (in shares)						122,000
Restricted Stock Units, Performance RSUs and PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)						726,000
Stock-based compensation expense						$ 100,000
Vested (in shares)						620,000
Service-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Number of awards granted (in shares)					982,301
Stock-based compensation expense						$ 500,000	400,000
Service-Based RSUs | Vesting Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Vesting percentage						25.00%
Service-Based RSUs | Vesting Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Vesting percentage						2.08%
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years			1 year
Number of awards granted (in shares)			100,000			23,196
Performance-Based RSUs | Vesting Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						6 months 1 day
RSUs and Performance RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense						$ 6,100,000	4,200,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	4,713,000					4,713,000		5,208,000
Number of awards granted (in shares)						726,000
Stock-based compensation expense						$ 3,800,000
Vested (in shares)					491,151
Service and Market-Based Options and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 1,400,000					$ 1,400,000
Unrecognized compensation expense, recognition period						2 years 6 months
Stock-based compensation expense						$ 200,000	400,000
Service and Market-Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options canceled (in shares)				196,460
Service and Market-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)					161,250
Canceled Market-based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense							200,000
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,843,000					1,843,000		890,000
Unrecognized compensation expense	$ 200,000					$ 200,000
Unrecognized compensation expense, recognition period						1 month 6 days
Stock-based compensation expense						$ 400,000
Issued in period (in shares)						0
RSUs Vested And Released [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares immediately vested in award modification (in shares)	11,412
Stock-based compensation expense recognized due to immediate vested in award modification	$ 100,000
2019 Employee Incentive Plan, Transferred From 2014 and 2008 Stock Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		21,770,029
2019 Employee Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		8,004,000
Annual increase in capital shares reserved for future issuance (in shares)		7,120,000
Percentage of outstanding stock maximum		4.00%
2019 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		890,000
Annual increase in capital shares reserved for future issuance (in shares)		2,670,000
Percentage of outstanding stock maximum		1.00%
Maximum payroll deduction		15.00%
Purchase price of common stock (percent)		85.00%
Maximum number of shares per employee (in shares)		500
Maximum value per employee		$ 12,500
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation related to capitalized internal-use software (less than)							$ 100,000
Maximum | 2019 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ownership percentage threshold to participate		5.00%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Shares Available for Grant and Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 30, 2019	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Shares Available for Grant
Balance as of December 31, 2019 (in shares)			8,160,000
Shares authorized (in shares)			3,812,000
Forfeited/cancelled (in shares)			144,000
Balance as of March 31, 2020 (in shares)			11,866,000	8,160,000
Shares Subject to Options Outstanding
Balance as of December 31, 2019 (in shares)			14,020,000
Exercised (in shares)			(1,247,000)
Forfeited/cancelled (in shares)			(144,000)
Balance as of March 31, 2020 (in shares)			12,629,000	14,020,000
Options vested and exercisable as of March 31, 2020 (in shares)			9,176,000
Weighted- Average Exercise Price
Balance as of December 31, 2019 (in USD per share)			$ 1.85
Exercised (in USD per share)			1.38
Forfeited/cancelled (in USD per share)			1.88
Balance as of March 31, 2020 (in USD per share)			1.89	$ 1.85
Options vested and exercisable as of June 30, 2019 (in USD per share)			$ 1.53
Weighted- Average Remaining Contractual Life (Years) and Aggregate Intrinsic Value
Weighted- Average Remaining Contractual Life (Years), Options outstanding			6 years 4 months 24 days	6 years 8 months 12 days
Weighted- Average Remaining Contractual Life (Years), Options vested and exercisable			6 years
Aggregate Intrinsic Value, Options outstanding			$ 336,424	$ 325,474
Aggregate Intrinsic Value, Options vested and exercisable			$ 247,727
Restricted Stock Awards
Shares Available for Grant
Granted (in shares)		(982,301)
Restricted stock units
Shares Available for Grant
Granted (in shares)			(726,000)
Performance stock units
Shares Available for Grant
Forfeited (in shares)			375,000
Performance-Based RSUs
Shares Available for Grant
Granted (in shares)	(100,000)		(23,196)
Forfeited (in shares)			101,000

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock Awards shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Shares
Unvested balance, December 31, 2019 (in shares) | shares	736
Vested (in shares) | shares	(122)
Unvested balance, March 31, 2020 (in shares) | shares	614
Weighted- Average Grant Date Fair Value
Unvested balance, December 31, 2019 (in USD per share) | $ / shares	$ 9.76
Vested (in USD per share) | $ / shares	9.76
Unvested balance, March 31, 2020 (in USD per share) | $ / shares	$ 9.76

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units, Performance RSUs and PSUs shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Shares
Unvested balance, December 31, 2019 (in shares) | shares	4,708
Issued (in shares) | shares	726
Vested (in shares) | shares	(620)
Forfeited (in shares) | shares	(101)
Unvested balance, March 31, 2020 (in shares) | shares	4,713
Weighted- Average Grant Date Fair Value
Unvested balance, December 31, 2019 (in USD per share) | $ / shares	$ 11.31
Issued (in USD per share) | $ / shares	24.41
Vested (in USD per share) | $ / shares	8.79
Forfeited (in USD per share) | $ / shares	17.95
Unvested balance, March 31, 2020 (in USD per share) | $ / shares	$ 13.52

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 8,063	$ 5,510
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	92	6
Research and development expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	2,216	361
Sales and marketing expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	2,052	219
General and administrative expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 3,703	$ 4,924

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income tax benefit	$ (21)	$ 1,388

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (5,573)	$ (14,371)
Accretion of redeemable convertible preferred stock	0	(41)
Net loss attributable to common stockholders	$ (5,573)	$ (14,412)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	95,543	18,207
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.06)	$ (0.79)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	18,738	78,121
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	0	58,615
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	12,629	16,757
Restricted stock awards subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	614	982
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	695	785
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	4,713	982
ESPP obligations
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	87	0

Segment Information (Details)

Segment Information (Details)	3 Months Ended
	Mar. 31, 2020segment
Segment Reporting [Abstract]
Number of operating segments	1

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Salary Under Employment Agreement
Related Party Transaction [Line Items]
Related party fees	$ 0

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Retirement Benefits [Abstract]
Plan expenses	$ 0.8	$ 0.4

Uncategorized Items - lvgo-2020

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 4,685,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 4,685,000